Industry & Business

Diaceutics signs multi-million-euro partnership with BioReference Laboratories

 Breaking News
  • Largest Ever European Investment Bank Support in Ireland The European Investment Bank is to provide a loan of €490 million to support construction of the new children’s hospital in Dublin. This represents the largest ever financial engagement by the European Union’s long-term lending institution in Ireland and the EIB’s first backing for a hospital in the country. The new children’s hospital project includes two [...]...
  • Strabane Manufacturer to Invest Over £7 Million in Ambitious Expansion Strabane-based Fabplus is planning to more than double its workforce and turnover with support from Invest Northern Ireland. The investment is part of a three year expansion plan to increase its market share in the Republic of Ireland and Great Britain, and gain a foothold in mainland Europe and Scandinavia. Recruitment is underway to employ 83 additional staff at [...]...
  • PM Group Appoints a New Non-Executive Director Michael McNicholas has been appointed as a Non-Executive Director of Project Management Holdings (PM Group), the Irish headquartered international project delivery specialists. Michael McNicholas. Michael has over 35 years’ experience in senior leadership positions in the public and private sectors. He is the former CEO of Ervia, NTR plc and Managing Director of ESB International.  During his [...]...
  • Center Parcs Signs Contract With John Sisk & Son As construction activity on the much anticipated €233 million Center Parcs Longford Forest resort in County Longford ramps up, the company has announced it has formally awarded two major construction contracts to Dublin-based construction firm John Sisk & Son. The contracts for the construction of the 470 lodges and 30 apartments as well as the state-of-the-art centre [...]...
  • Medi-Shower Invests in Innovation to Drive Export Growth Multi-award-winning manufacturer Medi-Shower has created ‘smart showerhead’ technology which can reduce the risk of Legionnaires disease. The cutting edge product, developed with R&D support from Invest Northern Ireland is designed to meet the high requirements for hygiene within the healthcare sector. It reduces the risk of waterborne infection from bacteria that can build up due to poor design [...]...

Diaceutics signs multi-million-euro partnership with BioReference Laboratories

Diaceutics signs multi-million-euro partnership with BioReference Laboratories
April 25
09:00 2017

Irish data insights and solutions company Diaceutics has announced a five-year multi-million-euro partnership with US-based BioReference Laboratories. The partnership will see Diaceutics acquire real-time testing data from BioReference, allowing it to help pharmaceutical companies achieve faster rollouts of new drugs through better understanding of the US diagnostics market.

Through its partnership with BioReference, which works with 30,000 healthcare providers across the US, Diaceutics will have access to data from 50,000 patient samples per day. Coupled with insights from BioReference, the real-time data will help improve patient testing by ensuring that pharmaceutical companies better understand the testing patterns of physicians considering precision medicine therapies for patients.

Currently, Diaceutics estimates that pharmaceutical companies are missing out on more than 20% of cancer patients every year in the US due to the challenging diagnostic landscape. With 70% of new drugs in the next five years expected to be test-dependent, Diaceutics expects that percentage will increase.

Peter Keeling, CEO, Diaceutics, said: “Diagnostic data from laboratories like BioReference helps pharmaceutical companies better understand the testing journey that patients go on in the often difficult search for a targeted therapy. That information allows pharma to pinpoint patients that need to be on a specific – and often life-changing – drug, accelerate speed to market for new drugs and improve patient outcomes.”

Diaceutics will integrate the data gathered from BioReference with its existing lab data accumulated through partnerships with other labs. Together, the data will allow Diaceutics to provide pharma with more complete, aggregated testing data that meets their very specific requirements – helping them to close the 20% patient gap in the oncology testing market and achieve a better return on new drug investments.

Keeling continues: “Timing is key for many patients Diaceutics strives to increase the number of patients correctly tested, therefore increasing the demand for new drugs – an attractive prospect for pharmaceutical companies – and ultimately significantly improving patient outcomes.

“We have seen first-hand the improved decision-making by our pharma clients when presented with the relevant data trends in specific disease areas. Enriching our real time and retrospective analytics with BioReference’s knowledgebase allows us to further map the diagnostic journey of patients and help pharmaceutical companies better understand how testing impacts precision prescribing. With this information, we can simply enable better decision making and investment in patient, physician and laboratory education.”

About Author

editor

editor

Related Articles






New Subscriber





Subscribe Here



Advertisements
































National Manufacturing Conference & Exhibition 2016

NIBRT Springboard Success Stories



Upcoming Events

  • No upcoming events
AEC v1.0.4